NCT01702857View on ClinicalTrials.gov

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico)

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

January 20, 2017

Study Completion Date

March 23, 2017

Conditions
Dengue Fever
Interventions
BIOLOGICAL

Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant

BIOLOGICAL

Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant

OTHER

Phosphate buffered saline

BIOLOGICAL

1 µg TDENV-PIV with Alum adjuvant

BIOLOGICAL

1 µg TDENV-PIV with AS01E adjuvant

Trial Locations (1)

00936-5067

Clinical Research Center, 1st Floor University Hospital, San Juan

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

lead

U.S. Army Medical Research and Development Command

FED

NCT01702857 - A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico) | Biotech Hunter | Biotech Hunter